ADIPOCYTE GROWTH AND PATHOGENESIS OF LIPOSARCOMA

脂肪细胞的生长和脂肪肉瘤的发病机制

基本信息

  • 批准号:
    6376022
  • 负责人:
  • 金额:
    $ 31.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1997
  • 资助国家:
    美国
  • 起止时间:
    1997-07-15 至 2003-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION: This project explores the molecular mechanisms involved in cellular transformation by the chimeric transcriptional regulatory protein TLS-CHOP that is encoded by the t(12:16) chromosomal rearrangement common to most myxoid and round cell liposarcomas. It is hypothesized that transformation in liposarcoma proceeds by two parallel pathways: (1) The CHOP component of the oncoprotein directs it to one set of target genes, and the TLS component deregulates their expression; (2) TLS-CHOP impinges on the normal function of the RNA-binding protein TLS, interfering with the proper expression of another set of target genes. The second component is predicted to be common to sarcomas that contain a TLS (or EWS) component in their causative oncoprotein. Members of both sets of target genes are hypothesized to function as effectors of the process of transformation. The goals of this project are, thus, to identify TLS-CHOP target genes, delineate the mechanism of their deregulation in liposarcoma, and determine their role in transformation. This will involve identifying genes contacted by TLS-CHOP and genes that are normally regulated by TLS, as well as identifying proteins that participate as partners in the process by which TLS-CHOP carried out its function. The latter include the direct cellular contingents of TLS and CHOP, as well as the products of genes that modify transformation indirectly. The identification of TLS-CHOP and TLS target genes will rely on the comparative analysis of the expression pattern of genes in cells that do and do not contain active forms of these regulators. The direct contingents of TLS and CHOP will be identified by biochemical and genetic means, whereas the identification of genes that modify the process of transformation by TLS-CHOP will be attained by a genetic screen of tumors derived in genetically-modified mice that will be developed as animal models for tumorigenesis by the oncoprotein.
描述:该项目探讨了参与的分子机制, 通过嵌合转录调节蛋白的细胞转化 TLS-CHOP由t(12:16)染色体重排编码, 大多数粘液样和圆细胞脂肪肉瘤。 它是假设 脂肪肉瘤的转化通过两条平行的途径进行:(1) 癌蛋白的CHOP组分将其引导至一组靶基因, TLS组分解除了它们的表达;(2)TLS-CHOP冲击了 RNA结合蛋白TLS的正常功能,干扰了正常的 另一组靶基因的表达。 第二组分是 预测是常见的肉瘤含有TLS(或EWS)成分, 它们的致癌蛋白。 两组靶基因的成员是 被假设为转化过程的效应器。 的 因此,该项目的目标是鉴定TLS-CHOP靶基因, 描述其在脂肪肉瘤中失调的机制,并确定 在转型中的作用。 这将涉及识别基因接触 通过TLS-CHOP和通常由TLS调节的基因,以及 识别作为伙伴参与过程的蛋白质, TLS-CHOP履行了其职能。 后者包括直接蜂窝 TLS和CHOP的特遣队,以及修改基因的产物, 间接转化。 TLS-CHOP和TLS靶标的识别 基因将依赖于比较分析的表达模式, 细胞中含有或不含有这些调节剂的活性形式的基因。 TLS和CHOP的直接特遣队将通过生物化学和 基因手段,而修改过程的基因的鉴定 通过TLS-CHOP的转化将通过肿瘤的遗传筛选来实现 来自将被开发为动物模型的转基因小鼠 癌蛋白引起的肿瘤。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Characterization of the CHOP breakpoints and fusion transcripts in myxoid liposarcomas with the 12;16 translocation.
具有 12;16 易位的粘液样脂肪肉瘤中 CHOP 断点和融合转录本的表征。
  • DOI:
  • 发表时间:
    1994
  • 期刊:
  • 影响因子:
    11.2
  • 作者:
    Panagopoulos,I;Mandahl,N;Ron,D;Hoglund,M;Nilbert,M;Mertens,F;Mitelman,F;Aman,P
  • 通讯作者:
    Aman,P
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID RON其他文献

DAVID RON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID RON', 18)}}的其他基金

Drug-like small molecule modulators of the Integrated Stress Response
综合应激反应的类药物小分子调节剂
  • 批准号:
    7996470
  • 财政年份:
    2009
  • 资助金额:
    $ 31.07万
  • 项目类别:
Screening for Inhibitors of the Integrated Stress Response
综合应激反应抑制剂的筛选
  • 批准号:
    7365462
  • 财政年份:
    2007
  • 资助金额:
    $ 31.07万
  • 项目类别:
Drug-like small molecule modulators of the Integrated Stress Response
综合应激反应的类药物小分子调节剂
  • 批准号:
    7263952
  • 财政年份:
    2006
  • 资助金额:
    $ 31.07万
  • 项目类别:
Drug-like small molecule modulators of the Integrated Stress Response
综合应激反应的类药物小分子调节剂
  • 批准号:
    7458067
  • 财政年份:
    2006
  • 资助金额:
    $ 31.07万
  • 项目类别:
Drug-like small molecule modulators of Integrated Stress
综合应激的类药物小分子调节剂
  • 批准号:
    7124080
  • 财政年份:
    2006
  • 资助金额:
    $ 31.07万
  • 项目类别:
Drug-like small molecule modulators of the Integrated Stress Response
综合应激反应的类药物小分子调节剂
  • 批准号:
    7638527
  • 财政年份:
    2006
  • 资助金额:
    $ 31.07万
  • 项目类别:
Endoplasmic Reticulum Stress and Parkinson's Disease
内质网应激与帕金森病
  • 批准号:
    6835944
  • 财政年份:
    2002
  • 资助金额:
    $ 31.07万
  • 项目类别:
Endoplasmic Reticulum Stress and Parkinson's Disease
内质网应激与帕金森病
  • 批准号:
    6625903
  • 财政年份:
    2002
  • 资助金额:
    $ 31.07万
  • 项目类别:
Endoplasmic Reticulum Stress and Parkinson's Disease
内质网应激与帕金森病
  • 批准号:
    6479891
  • 财政年份:
    2002
  • 资助金额:
    $ 31.07万
  • 项目类别:
ADIPOCYTE GROWTH AND PATHOGENESIS OF LIPOSARCOMA
脂肪细胞的生长和脂肪肉瘤的发病机制
  • 批准号:
    2895058
  • 财政年份:
    1997
  • 资助金额:
    $ 31.07万
  • 项目类别:

相似国自然基金

相似海外基金

New development of cellular regeneration therapy in jaw bone using stem cells derived from adipocytes jaw bone
利用颌骨脂肪细胞来源的干细胞进行颌骨细胞再生治疗的新进展
  • 批准号:
    23K16058
  • 财政年份:
    2023
  • 资助金额:
    $ 31.07万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
A novel mechanism of insulin resistance mediated by uric acid metabolism in adipocytes
脂肪细胞尿酸代谢介导胰岛素抵抗的新机制
  • 批准号:
    23K10969
  • 财政年份:
    2023
  • 资助金额:
    $ 31.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Hypertrophic adipocytes as biophysical mediators of breast cancer progression
肥大脂肪细胞作为乳腺癌进展的生物物理介质
  • 批准号:
    10751284
  • 财政年份:
    2023
  • 资助金额:
    $ 31.07万
  • 项目类别:
Development of adipocytes for gene therapy that avoids cellular stress due to overexpression of therapeutic proteins
开发用于基因治疗的脂肪细胞,避免因治疗蛋白过度表达而造成的细胞应激
  • 批准号:
    23H03065
  • 财政年份:
    2023
  • 资助金额:
    $ 31.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Functional analysis of bitter taste receptors in adipocytes and hepatocytes
脂肪细胞和肝细胞中苦味受体的功能分析
  • 批准号:
    23K05107
  • 财政年份:
    2023
  • 资助金额:
    $ 31.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Elucidation of mechanisms for conversion of adipocytes to cancer-associated fibroblasts in osteosarcoma microenvironment
阐明骨肉瘤微环境中脂肪细胞转化为癌症相关成纤维细胞的机制
  • 批准号:
    23K19518
  • 财政年份:
    2023
  • 资助金额:
    $ 31.07万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Study on UCP-1 independent metabolic regulation by brown adipocytes
棕色脂肪细胞对UCP-1独立代谢调节的研究
  • 批准号:
    23K18303
  • 财政年份:
    2023
  • 资助金额:
    $ 31.07万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
NKA/CD36 signaling in adipocytes promotes oxidative stress and drives chronic inflammation in atherosclerosis
脂肪细胞中的 NKA/CD36 信号传导促进氧化应激并驱动动脉粥样硬化的慢性炎症
  • 批准号:
    10655793
  • 财政年份:
    2023
  • 资助金额:
    $ 31.07万
  • 项目类别:
The mechanisms of the signal transduction from brown adipocytes to afferent neurons and its significance.
棕色脂肪细胞向传入神经元的信号转导机制及其意义。
  • 批准号:
    23K05594
  • 财政年份:
    2023
  • 资助金额:
    $ 31.07万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Characterizing breast cancer invasion and proliferation when co-aggregated with adipocytes in multicellular spheroids created with a custom bioreactor to augment cell-cell connectivity.
当与多细胞球体中的脂肪细胞共聚集时,表征乳腺癌的侵袭和增殖,该多细胞球体是用定制生物反应器创建的,以增强细胞间的连接。
  • 批准号:
    10334113
  • 财政年份:
    2022
  • 资助金额:
    $ 31.07万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了